A Phase 1, Open-Label, Multiple-Dose, Dose Escalation Study to Assess the Safety, Tolerability and Pharmacokinetics of AZD8931 in Patients With Advanced Solid Malignancies.
Phase of Trial: Phase I
Latest Information Update: 11 Mar 2013
At a glance
- Drugs Sapitinib (Primary)
- Indications Solid tumours
- Focus Adverse reactions
- 01 Dec 2012 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov record.
- 31 Jul 2012 Planned end date changed from 1 Aug 2012 to 1 Feb 2013 as reported by ClinicalTrials.gov record.
- 14 Feb 2012 Additional lead trial investigator (Serban Ghiorghiu) identified as reported by ClinicalTrials.gov.